Results 11 to 20 of about 279,790 (190)
CAR T Cell Therapy for Neuroblastoma [PDF]
Frontiers in Immunology, 2018 Patients with high risk neuroblastoma have a poor prognosis and survivors are often left with debilitating long term sequelae from treatment. Even after integration of anti-GD2 monoclonal antibody therapy into standard, upftont protocols, 5-year overall ...
Rebecca M. Richards +2 more
doaj +3 more sources
CAR-T CELL THERAPY FOR T-CELL MALIGNANCIES
Mediterranean Journal of Hematology and Infectious DiseasesChimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment of B-cell lymphoid neoplasia and, in some instances, improved disease outcomes.
Ugo Testa +4 more
doaj +3 more sources
Reactions WeeklyChimeric antigen receptor T-cell (CAR-T) therapy has rapidly reshaped the therapeutic landscape for children and adolescents with relapsed or refractory hematologic malignancies. In Brazil, the integration of CAR-T therapy into pediatric oncology practice faces unique logistical, regulatory, and socioeconomic challenges, highlighting the need for ...
Antonella Zanette +6 more
+13 more sources
CAR-T cell therapy in nephrology. [PDF]
Ren FailIn recent years, chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a promising immunotherapeutic strategy beyond oncology, offering new treatment opportunities for immune-mediated kidney diseases. These conditions including systemic lupus erythematosus, ANCA-associated vasculitis, membranous nephropathy, and monoclonal gammopathy-related ...
Tondolo F +6 more
europepmc +5 more sources
CAR-T Cell Therapy for Lymphoma [PDF]
Annual Review of Medicine, 2016 Lymphomas arise from clonal expansions of B, T, or NK cells at different stages of differentiation. Because they occur in the immunocyte-rich lymphoid tissues, they are easily accessible to antibodies and cell-based immunotherapy. Expressing chimeric antigen receptors (CARs) on T cells is a means of combining the antigen-binding site of a monoclonal ...
Carlos A, Ramos +2 more
openaire +2 more sources
Mathematical deconvolution of CAR T-cell proliferation and exhaustion from real-time killing assay data. [PDF]
, 2020 Chimeric antigen receptor (CAR) T-cell therapy has shown promise in the treatment of haematological cancers and is currently being investigated for solid tumours, including high-grade glioma brain tumours.
Abler, Daniel +13 more
core +2 more sources
International Journal of Molecular Sciences, 2020 CAR-T therapy has revolutionized the treatment of select hematological malignancies, namely, acute lymphoblastic leukemia and large B-cell lymphomas [...]
openaire +2 more sources
Cancer Stem Cell as Target of CAR-T Cell Therapy [PDF]
E3S Web of Conferences, 2020 Chimeric antigen receptor-T cell (CAR-T) therapy has been studied intensively these years and is considered a promising cancer treatment. So far, Food and Drug Administration has approved 2 CAR-T cell therapy for patients with refractory leukemia and the
Li Xinran
doaj +1 more source
Revealing Facts About CAR-T Cell Therapy [PDF]
ImmunoAnalysis, 2022 Chimeric antigen receptor (CAR)-T cell therapy is a fast-emerging treatment for several types of cancers and has several applications beyond oncology. It is a new emerging treatment targeting for a broad range of cancers.
Daggupati Sai Padmanjali +2 more
doaj +1 more source
Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy [PDF]
, 2020 Chimeric antigen receptor (CAR) T-cell therapy has produced remarkable anti-tumor responses in patients with B-cell malignancies. However, clonal kinetics and transcriptional programs that regulate the fate of CAR-T cells after infusion remain poorly ...
Adair, Jennifer E. +16 more
core +1 more source